ATE397939T1 - STABILIZED LIQUID PREPARATION OF THE BLOOD CLOTTING FACTOR VII ACTIVATE PROTEASE OR ITS PROENZYME - Google Patents

STABILIZED LIQUID PREPARATION OF THE BLOOD CLOTTING FACTOR VII ACTIVATE PROTEASE OR ITS PROENZYME

Info

Publication number
ATE397939T1
ATE397939T1 AT01129605T AT01129605T ATE397939T1 AT E397939 T1 ATE397939 T1 AT E397939T1 AT 01129605 T AT01129605 T AT 01129605T AT 01129605 T AT01129605 T AT 01129605T AT E397939 T1 ATE397939 T1 AT E397939T1
Authority
AT
Austria
Prior art keywords
factor vii
stabilized liquid
proenzyme
liquid preparation
blood clotting
Prior art date
Application number
AT01129605T
Other languages
German (de)
Inventor
Juergen Roemisch
Annette Feussner
Christian Kannemeier
Hans-Arnold Stoehr
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of ATE397939T1 publication Critical patent/ATE397939T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A stabilized liquid formulation (A), comprises: (A) blood coagulation Factor VII activating protease (or its pro-enzyme) (I); and (B) at least one aminoacid or derivative (II). A stabilized liquid formulation (A), comprises: (A) blood coagulation Factor VII activating protease (or its pro-enzyme) (I); and (B) at least one aminoacid or derivative (II) selected from ornithine. diaminopimelic acid, agmatine, creatine, guanidinoacetic acid, acetylornithine, citrulline, arginino-succinic acid, tranexamic acid and iota -aminocaproic acid (including their salts or derivatives).
AT01129605T 2001-01-08 2001-12-12 STABILIZED LIQUID PREPARATION OF THE BLOOD CLOTTING FACTOR VII ACTIVATE PROTEASE OR ITS PROENZYME ATE397939T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10100483 2001-01-08
DE10131404A DE10131404A1 (en) 2001-01-08 2001-06-25 Stabilized liquid formulation, useful as a pharmaceutical composition or diagnostic reagent, comprises blood coagulation Factor VII activating protease and an aminoacid or derivative, e.g. ornithine or creatine, as stabilizer

Publications (1)

Publication Number Publication Date
ATE397939T1 true ATE397939T1 (en) 2008-07-15

Family

ID=7669938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01129605T ATE397939T1 (en) 2001-01-08 2001-12-12 STABILIZED LIQUID PREPARATION OF THE BLOOD CLOTTING FACTOR VII ACTIVATE PROTEASE OR ITS PROENZYME

Country Status (3)

Country Link
AT (1) ATE397939T1 (en)
DE (1) DE10131404A1 (en)
ES (1) ES2307561T3 (en)

Also Published As

Publication number Publication date
ES2307561T3 (en) 2008-12-01
DE10131404A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
EP1226829A3 (en) Stabilised liquid preparations of the protease or its proenzyme which activitate the blood coagulation factor VII
NO993709D0 (en) Stabilized composition comprising fibrinogen
CY1110516T1 (en) REVERSE DISABLED ACIDIZED PLASTIC
DE50211045D1 (en) MEDICAL AEROSOL FORMULATIONS
ATE254928T1 (en) STABILIZED COMPOSITION WITH NOOTROPIC ACTIVE INGREDIENTS
NO2013003I2 (en) Compounds as NS3 serine protease inhibitors for hepatitis C virus, pharmaceutical preparations and use of the compounds in the manufacture of a medicament
DK0558529T3 (en) Pharmaceutical preparation for treatment of prolonged clotting time
BRPI0408439A (en) aqueous liquid pharmaceutical composition, method for preparing and using same, method for treating a factor responsive syndrome vii, and, airtight container
CY1111905T1 (en) PHARMACEUTICAL COMPOSITION OF INCLUDING AN OPTIONAL INSPECTOR OF AMINOPRIDA A, SPECIFICALLY IN EC33, TO REDUCE BLOOD
ES2139740T3 (en) TWO-COMPONENT FIBRINE GLUE.
DK1290011T3 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
DE69932860D1 (en) USE OF L-CARNITINE AND ITS ALKANOYL DERIVATIVES AS AN OSMOTIC AGENT IN MEDICAL USE SOLUTIONS
DE502004011851D1 (en) Caspase 3, 8, 9 or 10 inhibitors in combination with MEK inhibitors for the treatment of influenza
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
DE60101486D1 (en) Use of polyamino acid derivatives as a preservative
DK1648496T3 (en) A method of stabilizing a cryoprecipitate of plasmatic proteins intended to be subjected to a heat treatment for virus inactivation
DE50203283D1 (en) PREPARATION FOR THE REMOVAL OF ABNORMENTS OF KERATIN MATERIAL
ATE397939T1 (en) STABILIZED LIQUID PREPARATION OF THE BLOOD CLOTTING FACTOR VII ACTIVATE PROTEASE OR ITS PROENZYME
ATE395064T1 (en) COMBINATION PREPARATIONS OF 3-N-FORMYLHYDROXYLAMINOPROPYLPHOSPHONY ACID DERIVATIVES OR 3-N-ACETYLHYDROXYLAMINOPROPYLPHOSPHONY ACID DERIVATIVES WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS
DE50111407D1 (en) MEDIUM CONTAINING N-CHLORTAURINE AND ITS USE FOR THE TREATMENT OF TREATMENT POLYPES
WO2003028654A3 (en) Storage-stable human fibrinogen solutions
DK1341813T3 (en) Use of L-carnitine as a stabilizer of proteins
ATE538782T1 (en) MODIFIED AMINO ACIDS 5-CNAC FOR INHIBITING THROMBOCYTE AGGREGATION
Reddy Dialysis Clinic Argatroban Use in Dialysis Patients.
BRPI0410021A (en) solid pharmaceutical preparation containing levothyroxine and / or lyothyronine salts as active substance